Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | MVD | P53602 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6562015 | 1.00 | ACE (0.54) | ACEABCC4MAPTRAB9AREN | |
| SCHEMBL4478131 | 1.00 | ACE (0.54) | ACEABCC4MAPTRAB9AREN | |
| SCHEMBL4613053 | 1.00 | ACE (0.54) | ACEABCC4MAPTRAB9AREN | |
| SCHEMBL14586443 | 0.88 | ACE (0.59) | ACERAB9ARENMVDCHRM2 | |
| SCHEMBL10005864 | 0.88 | ACE (0.59) | ACERAB9ARENMVDCHRM2 | |
| SCHEMBL10005860 | 0.88 | ACE (0.59) | ACERAB9ARENMVDCHRM2 | |
| SCHEMBL7298458 | 0.88 | ACE (0.66) | ACERENMVDCHRM2CHRM4 | |
| SCHEMBL6789458 | 0.88 | ACE (0.66) | ACERENMVDCHRM2CHRM4 | |
| SCHEMBL6784027 | 0.88 | ACE (0.66) | ACERENMVDCHRM2CHRM4 | |
| SCHEMBL6789464 | 0.88 | ACE (0.66) | ACERENMVDCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524933-B2 | In or relating to organic compounds | GIVAUDAN SA (CH) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524933-B2 | In or relating to organic compounds | GABRB3, GABRB1, GABRB2 | ACE 4102/4885ABCC4 3715/4885MAPT 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.